Cutia Therapeutics HK$412.9 million IPO
We advised Cutia on its IPO and HKEX listing
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Akoya Biosciences $50 million follow-on offering
The stock is listed on Nasdaq
Ionis Pharmaceuticals $575 million convertible senior notes offering
The 1.75% convertible senior notes are due 2028
Oculis Holding $40.25 million debut equity offering
The shares are listed on the Nasdaq Global Market
TScan Therapeutics $140.6 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Market
Coherus BioSciences $57.5 million follow-on offering
The stock is listed on the Nasdaq Global Market
Emergent BioSolutions $150 million at-the-market offering
The shares are listed on the NYSE
Forbion European Acquisition combination with enGene
We are advising Forbion European Acquisition on its de-SPAC transaction
Merck $6 billion notes offering
The investment-grade notes offering consists of six tranches
GSK exclusive licensing agreement with Scynexis
We advised GSK on the transaction